Analysts expect that Natera Inc (NASDAQ:NTRA) will post earnings per share (EPS) of ($0.52) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Natera’s earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.41). Natera also posted earnings per share of ($0.52) during the same quarter last year. The company is expected to announce its next earnings report on Tuesday, August 14th.
On average, analysts expect that Natera will report full-year earnings of ($2.02) per share for the current year, with EPS estimates ranging from ($2.23) to ($1.81). For the next financial year, analysts expect that the business will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.09) to ($0.65). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Natera.
Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, May 8th. The medical research company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.01). Natera had a negative net margin of 58.84% and a negative return on equity of 752.93%. The firm had revenue of $62.34 million during the quarter, compared to analyst estimates of $54.86 million. During the same period in the prior year, the company posted ($0.70) earnings per share. The firm’s revenue for the quarter was up 26.2% compared to the same quarter last year.
Shares of NTRA traded down $0.07 during midday trading on Monday, reaching $22.87. The company had a trading volume of 1,006,246 shares, compared to its average volume of 290,233. Natera has a 1-year low of $7.78 and a 1-year high of $24.07. The company has a market capitalization of $1.24 billion, a PE ratio of -9.53 and a beta of 2.00. The company has a quick ratio of 1.68, a current ratio of 1.80 and a debt-to-equity ratio of -18.90.
In related news, major shareholder Claremont Creek Partners Fund sold 37,540 shares of the firm’s stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $11.48, for a total transaction of $430,959.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Steven Leonard Chapman sold 86,919 shares of the firm’s stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $18.00, for a total value of $1,564,542.00. Following the sale, the chief operating officer now directly owns 3,588 shares of the company’s stock, valued at $64,584. The disclosure for this sale can be found here. Insiders sold a total of 178,364 shares of company stock valued at $2,801,816 over the last ninety days. Corporate insiders own 13.18% of the company’s stock.
Large investors have recently modified their holdings of the stock. Trexquant Investment LP acquired a new stake in shares of Natera during the 1st quarter worth about $119,000. MetLife Investment Advisors LLC acquired a new stake in shares of Natera during the 4th quarter worth about $124,000. Jefferies Group LLC acquired a new stake in shares of Natera during the 4th quarter worth about $130,000. A.R.T. Advisors LLC acquired a new stake in shares of Natera during the 1st quarter worth about $164,000. Finally, Swiss National Bank increased its position in shares of Natera by 13.2% during the 1st quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock worth $444,000 after purchasing an additional 5,600 shares during the last quarter. 69.76% of the stock is owned by hedge funds and other institutional investors.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Closed-End Mutual Funds (CEFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.